Company intelligence / Profile preview

ADVENTRX

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

ADVENTRX Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing proprietary product candidates for critical care and oncology. The company's lead program was ANX-188 (vepoloxamer), a rheologic and cytoprotective agent designed to improve blood flow and reduce tissue damage in sickle cell disease. ADVENTRX also utilized its emulsion technology to develop improved versions of chemotherapy drugs, such as Exelbine (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), aimed at reducing toxicity. In 2013, the company rebranded as Mast Therapeutics, which later merged with Savara Inc. in 2017. The company was headquartered in San Diego, California, and was publicly traded on the NYSE MKT exchange.

Therapeutic areas: HematologyOncology
Modalities: Small moleculePolymer
Industry: Biotech

Beyond the preview

Go deeper on ADVENTRX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADVENTRX.

Explore the full profile